Zacks Investment ResearchTue, 07 Jul 2026 17:11:07 GMTWill Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?REGN-1.08%
Zacks Investment ResearchTue, 07 Jul 2026 14:41:13 GMTHere's Why Regeneron (REGN) is a Strong Value StockREGN-1.08%
Zacks Investment ResearchThu, 02 Jul 2026 14:51:08 GMTWhy Regeneron (REGN) is a Top Momentum Stock for the Long-TermREGN-1.08%
The Motley FoolSun, 28 Jun 2026 00:00:00 GMTThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already InvestedREGN-1.08%
Zacks Investment ResearchTue, 23 Jun 2026 19:26:10 GMTRegeneron's Applications for gMG Drug Accepted by FDA and EMAREGN-1.08%
Zacks Investment ResearchFri, 12 Jun 2026 14:41:12 GMTHere's Why Regeneron (REGN) is a Strong Value StockREGN-1.08%
Seeking AlphaMon, 08 Jun 2026 21:38:30 GMTRegeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptREGN-1.08%
Seeking AlphaMon, 08 Jun 2026 06:48:49 GMTRegeneron: 'Buy' Revenue Growth And Two Extensive Drug Development OpportunitiesREGN-1.08%
Zacks Investment ResearchThu, 04 Jun 2026 18:25:14 GMTREGN Expands Cancer Deal With CytomX for Bispecific TherapeuticsREGN-1.08%
Zacks Investment ResearchMon, 01 Jun 2026 15:35:11 GMTRegeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)REGN-1.08%
Zacks Investment ResearchMon, 01 Jun 2026 15:35:10 GMTRegeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)REGN-1.08%
Zacks Investment ResearchFri, 29 May 2026 16:31:47 GMTRegeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?REGN-1.08%
24/7 Wall StreetThu, 28 May 2026 15:04:00 GMTThese 2 Cheap Biotech Stocks Offer Potential for Low-Beta GrowthREGN-1.08%
Zacks Investment ResearchFri, 22 May 2026 14:41:11 GMTHere's Why Regeneron (REGN) is a Strong Value StockREGN-1.08%
Zacks Investment ResearchTue, 19 May 2026 19:30:54 GMTRegeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2BREGN-1.08%
Zacks Investment ResearchTue, 19 May 2026 16:56:07 GMTCan Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?REGN-1.08%
InvezzMon, 18 May 2026 19:25:19 GMTRegeneron stock drops double digits on oncology trial failureREGN-1.08%
Zacks Investment ResearchMon, 18 May 2026 19:17:19 GMTRegeneron's Late-Stage Melanoma Study Misses Primary GoalREGN-1.08%
Seeking AlphaMon, 18 May 2026 16:01:00 GMTRegeneron: Time To Forget Fianlimab (Rating Upgrade)REGN-1.08%
WSJMon, 18 May 2026 11:04:00 GMTRegeneron Shares Slide Premarket after Melanoma Drug Trial DisappointsREGN-1.08%
